Kymera Therapeutics Inc.

NASDAQ: KYMR
Share price (8/15/25): $42.63
Market cap (8/15/25): $3.048 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Automatic shelf registration

Prospectus supplement for primary offering

Ownership Filter

Wellington Management Group Llp

Biotechnology Value Fund L P, Bvf Partners L P/Il, Bvf Inc/Il, Biotechnology Value Fund II LP, Lampert Mark N, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., Bvf I GP LLC, Bvf II GP LLC, Bvf GP Holdings LLC

Baker Bros. Advisors LP

Baker Julian, Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (GP) LLC

News Filter

Announces Second Quarter 2025 Financial Results and Provides a Business Update

Announces Proposed Public Offering

Shareholder Vote Results

Announces Sanofi IRAK4 Collaboration Update

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue Cdk2 Degraders

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Letter from the SEC

Correspondence with the SEC

Scanned paper annual report submission

Letter from the SEC

Scanned paper annual report submission